Hybrid Coronary Revascularization in Selected Patients With Multivessel Disease

Tajstra, Mateusz; Hrapkowicz, Tomasz; Hawranek, Michał; Filipiak‬, Krzysztof J.; Gierlotka, Marek; Zembala, Marian; Gąsior, Mariusz; Zembala, Michael O.; Investigators, Pol-Mides Study

doi:10.1016/j.jcin.2018.01.271

Cited by 77 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…83 Hybrid coronary revascularization does not have significant lower 1-and 5-year mortality, nor AMI, stroke, major bleeding, or repeated revascularization compared to CABG. 85,88,89 Minimally invasive and hybrid procedures are less comprehensive surgeries with few complications and shorter recovery time, which might give patients with high comorbidities an option to perform heart surgery.…”

Section: Minimally Invasive and Hybrid Proceduresmentioning

confidence: 99%

Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis

Brynildsen

Myhre

Lyngbakken

et al. 2019

Clinical Biochemistry

View full text Add to dashboard Cite

show abstract

Section: Minimally Invasive and Hybrid Proceduresmentioning

confidence: 99%

Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis

Brynildsen

Myhre

Lyngbakken

et al. 2019

Clinical Biochemistry

View full text Add to dashboard Cite

show abstract

“…The major benefits of HCR are the avoidance of a sternotomy, clamping of the aorta, and use of cardiopulmonary bypass, while maintaining the survival benefit of the LITA-LAD anastomosis, and the minimally invasive character of PCI. 5 Several studies have shown similar short-term results between the gold standard CABG and HCR in terms of short-term mortality, major adverse cardiac and cerebrovascular events, and short-term patency rates. 6 -8 Thus, HCR is suggested to be a safe and promising procedure, but long-term outcomes and patency rates remain understudied.…”

Section: Introductionmentioning

confidence: 86%

Five-Year Outcomes After Hybrid Coronary Revascularization: A Single Center Experience

Jong

Jacob

Jalali

et al. 2021

Innovations�(Phila)

View full text Add to dashboard Cite

Objective Hybrid coronary revascularization (HCR) combines both surgical and percutaneous coronary revascularization procedures. It offers a minimally invasive strategy for multivessel coronary artery disease and combines the advantages of both. However, quantitative long-term patency and clinical outcomes remain understudied. The objective of this study was to assess clinical outcomes and graft and stent patency at 5-year follow-up. Methods From January 2004 to January 2015, 120 patients were enrolled in this study. They underwent robotically assisted minimally invasive coronary artery bypass grafting of left internal thoracic artery (LITA) to the left descending artery (LAD) and percutaneous coronary intervention of non-LAD vessels. Primary outcome was graft (LITA-LAD) patency determined at 5 years of follow-up, assessed by computed tomography angiography and rest and stress myocardial perfusion scintigraphy (MPS-MIBI). Secondary outcomes were stent patency and major adverse major cardiac and cerebrovascular events (MACCE). Also, freedom from recurrence of angina was assessed. Results At follow-up, 18 of 120 patients (15%) had died (in 5 patients the cause of death was cardiovascular). Among survivors, follow-up was achieved in 83 of 102 (81%). In 76 of 83 patients (92%) there was a patent LITA-LAD graft and in 75 of 83 (90%) a patent stent was demonstrated. MACCE occurred in 36 of 120 patients (30%). Freedom from recurrence of angina occurred in 92 of 120 patients (77%). Conclusions HCR is a safe and a promising procedure. It provides a minimally invasive approach and results in complete revascularization with good 5-year patency and clinical outcomes.

show abstract

“…Current data points toward similar outcomes to traditional CABG. 97 , 99 This option is not common practice and the lack of large prospective analysis limits widespread use.…”

Section: Section III Cabg Now and Pci For The Future?mentioning

confidence: 99%

Coronary revascularization in patients with stable coronary disease and diabetes mellitus

Bhat

Yatsynovich

Sharma

2021

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Purpose of Study: Diabetes mellitus accelerates the development of atherosclerosis. Patients with diabetes mellitus have higher incidence and mortality rates from cardiovascular disease and undergo a disproportionately higher number of coronary interventions compared to the general population. Proper selection of treatment modalities is thus paramount. Treatment strategies include medical management and interventional approaches including coronary artery bypass graft (CABG) surgery and percutaneous coronary interventions (PCI). The purpose of this review is to assimilate emerging evidence comparing CABG to PCI in patients with diabetes and present an outlook on the latest advances in percutaneous interventions, in addition to the optimal medical therapies in patients with diabetes. Key Methods: A systematic search of PubMed, Web of Science and EMBASE was performed to identify prospective, randomized trials comparing outcomes of CABG and PCI, and also PCI with different generations of stents used in patients with diabetes. Additional review of bibliography of selected studies was also performed. Main Conclusions: Most of the trials discussed above demonstrate a survival advantage of CABG over PCI in patients with diabetes. However, recent advances in PCI technology are starting to challenge this narrative. Superior stent designs, use of specific drug-eluting stents, image-guided stent deployment, and the use of contemporary antiplatelet and lipid-lowering therapies are continuing to improve the PCI outcomes. Prospective data for such emerging interventional technologies in diabetes is however lacking currently and is the need of the hour.

show abstract

Hybrid Coronary Revascularization in Selected Patients With Multivessel Disease

Abstract: HCR has similar 5-year all-cause mortality when compared with conventional coronary bypass grafting (Safety and Efficacy Study of Hybrid Revascularization in Multivessel Coronary Artery Disease; NCT01035567).

Cited by 77 publications

References 25 publications

Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis

Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis

Five-Year Outcomes After Hybrid Coronary Revascularization: A Single Center Experience

Coronary revascularization in patients with stable coronary disease and diabetes mellitus

Contact Info

Product

Resources

About